Flosequinan

Title: Flosequinan
CAS Registry Number: 76568-02-0
CAS Name: 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone
Additional Names: flosequinon
Manufacturers' Codes: BTS-49465
Trademarks: Manoplax (Boots)
Molecular Formula: C11H10FNO2S
Molecular Weight: 239.27
Percent Composition: C 55.22%, H 4.21%, F 7.94%, N 5.85%, O 13.37%, S 13.40%
Literature References: Mixed arterial and venous vasodilator. Prepn: R. V. Davies et al., DE 3011994; eidem, US 4302460 (1980, 1981 both to Boots). Pharmacology: J. G. Smith, G. T. Kinasewitz, J. Cardiovasc. Pharmacol. 8, 878 (1986); M. F. Sim et al., Br. J. Pharmacol. 94, 371 (1988). HPLC determn in plasma, serum and urine: M. B. Slegowski et al., J. Chromatogr. 425, 227 (1988). Pharmacokinetics and hemodynamics in humans: A. J. Cowley et al., J. Hypertens. 2, Suppl. 3, 547 (1984); R. D. Wynne et al., Eur. J. Clin. Pharmacol. 28, 659 (1985). Preliminary evaluation in hypertension: A. J. Cowley et al., ibid. 33, 203 (1987); in congestive heart failure: P. D. Kessler, M. Packer, Am. Heart J. 113, 137 (1987); P. D. Kessler et al., J. Cardiovasc. Pharmacol. 12, 6 (1988). Clinical study in chronic heart failure: A. J. Cowley et al., Br. Med. J. 297, 169 (1988).
Properties: Crystals, mp 226-228°.
Melting point: mp 226-228°
Therap-Cat: Antihypertensive.
Keywords: Antihypertensive.
Floxacillin Floxuridine Fluacizine Fluanisone Fluazacort

Flosequinan
Flosequinan.svg
Systematic (IUPAC) name
(RS)-7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one
Clinical data
Legal status  ?
Identifiers
CAS number 76568-02-0
ATC code C01DB01
PubChem CID 4474062
UNII 6NB119DLU7 YesY
KEGG D04195 YesY
Chemical data
Formula C11H10FNO2S 
Mol. mass 239.267 g/mol
 YesY (what is this?)  (verify)

Flosequinan is a quinolone vasodilator. It has direct relaxing effects on peripheral arteries and veins. It is administered orally in cases of congestive heart failure in patients who are not responsive to digitalis or ACE inhibitors. It was sold under the trade name Manoplax.

It was withdrawn from the US market in October 1993 due to an increased risk of hospitalization or death.[1]